News Tocagen’s brain tumour candidate gets PRIME designation An early-stage drug candidate for hard-to-treat brain tumours has been granted special ‘PRIME’ status by the European Medicines Agency.
News Tocagen aims for IPO to fund brain cancer trial Brain cancer specialist Tocagen is to become the latest biotech to test the waters with an IPO this year, after mixed success for recent market launches.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
